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Background: Although hyponatremia has prognostic implications in acute decompensated heart failure (ADHF), its influence on patient clinical 
course, including response to diuretics and renal function, has not been reported. Our objective was to evaluate the incidence of hyponatremia in 
ADHF and its association with treatment responses and clinical outcomes.
Methods: A retrospective cohort study was conducted in hospitalized ADHF patients treated with intravenous loop diuretics for ≥48 hours. The 
association of hyponatremia, stratified by severity, to diuretic response, intravenous vasoactive therapies, ACEi/ARB therapy, renal function, and 
hypotension was assessed. Comparison between new onset hyponatremia (acute) versus hyponatremia present on admission (chronic) was also 
performed.
Results: 499 patients were included (mean age 57±13y, 65% male, LVEF 40±17%) with hyponatremia occurring in 54%. Diuretic and ACEi/ARB 
doses were standardized to furosemide and enalapril equivalents. Results are summarized in the table. Disparities to normonatremic patients for 
outcomes were similar regardless of whether hyponatremia was acute or chronic (data not shown). 
Nadir sodium, mEq/L ≥ 135 130-134 < 130 p-value
N 232 179 88
Initial diuretic dose,
mg 65±43 75±84 71±55 0.276
Maximum diuretic dose,
mg 84±132 114±165 248±450 <0.001
Diuretic resistance, % 11 16 44 <0.001
Mean hourly urine
output, mL 79±37 85±43 80±36 0.234
IV vasodilator, % 43 48 56 0.125
IV inotrope, % 4 17 38 <0.001
IV vasopressor, % 1 5 19 <0.001
ACEi/ARB initial dose,
mg 11.7±11.8 10.7±11.6 7.8±8.9 0.024
ACEi/ARB discharge
dose, mg 11.0±13.0 9.6±12.7 5.7±9.0 0.003
Scr baseline, mg/dL 1.38±1.32 1.24±0.95 1.21±0.79 0.334
Scr change @ peak,
mg/dL 0.20±0.26 0.35±0.45 0.63±1.00 <0.001
BUN baseline, mg/dL 26±19 25±15 27±18 0.604
BUN change @ peak,
mg/dL 7±8 11±14 16±16 <0.001
Acute worsening renal
function
(Scr ≥0.3mg/dL or 25%)
27 45 62 <0.001
Sustained hypotension,
% 28 39 58 <0.001
Length of stay, days 4.9±3.6 7.7±7.1 14.0±8.9 <0.001
In-hospital mortality,
% 1.3 0.6 5.7 0.009
Conclusion: Acute or chronic hyponatremia, especially <130 mEq/L, in ADHF patients is associated with the need for greater diuretic doses and 
IV vasoactive therapies, and a higher incidence of worsening renal function and poorer outcomes. Alternative treatments warrant evaluation in these 
patients.
